NKGen Biotech Korea (182400)

KOSDAQ · 3,670 KRW · As of Aug 26, 2026 close

1Y Close · As of Aug 26, 2026

Mkt Cap

265.5B

Rev (2025)

7.9B

Op Inc (2025)

-2.5B

Net Inc (2025)

-7.3B

PBR

37.42

52W

3K~3K

NKGen Biotech Korea operates in the Pharmaceuticals sector.

Legal name: NKGen Biotech Korea Co., Ltd.

In fiscal year 2025, NKGen Biotech Korea (182400) reported revenue of 7.9 billion KRW, down 10.7% from 8.8 billion KRW a year earlier.

Operating profit was -2.5 billion KRW and net income was -7.3 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 265.5 billion KRW, with a P/B of 37.42.

These figures can be verified in the DART filing (receipt no. 20260324000530).

Year	Rev	Op Inc	Net Inc
2025	7.9B	-2.5B	-7.3B
2024	8.8B	-4.1B	-36.9B
2023	9.9B	-67.3B	-153.4B

3 applicable out of 8 items

Semi-Annual Report (2026.06)

Checks

3 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: 1 administrative designation criteria met. [source]

Audit Opinion: Audit opinion: Unqualified (clean).

Convertible Bonds: Convertible bonds outstanding with 0.01% potential dilution.

Capital Increase: No capital-increase filings in the last 180 days.

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: 3 market action(s) (trading halt, delisting, etc.) recorded. [source]

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.

Date	Filing
2026-08-13	Semi-Annual Report (2026.06)